- In October 2022, at ASM Microbe 2022 in Washington, DC, Microbion Corporation presented promising findings regarding pravibismane's impact on bacterial energetics in species like Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Mycobacterium avium. The compound was shown to disrupt bacterial bioenergetics and protein synthesis effectively
- In September 2022, Oxford Immunotec received FDA approval for its T-Cell Select reagent kit, designed to streamline the workflow of the T-SPOT.TB test. This globally regulated ELISPOT IGRA test detects latent tuberculosis (TB) infection and is intended for in-vitro diagnostic use in certified laboratories
